Impact of intensive blood pressure lowering on atrial fibrillation risk in hypertensive patients: A systematic review and meta-analysis
10.1097/st9.0000000000000069
- Author:
Wenxi ZUO
1
;
Yuhe HUANG
2
;
Ziyi SUN
3
;
Yuhan YANG
3
;
Jin ZHANG
3
;
Xiaoxiao ZHANG
1
;
Kuiwu YAO
4
Author Information
1. Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
2. College of Education, Chengdu College of Arts and Sciences, Chengdu, China
3. Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China; Beijing University of Chinese Medicine, Beijing, China
4. Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China; Academic Administration Office, China Academy of Chinese Medical Sciences, Beijing, China
- Publication Type:Journal Article
- Keywords:
Hypertension;
Atrial fibrillation;
Intensive blood pressure lowering;
Cardiovascular events
- From:
Science of Traditional Chinese Medicine
2025;3(2):186-193
- CountryChina
- Language:English
-
Abstract:
Background: Hypertension is a major risk factor for cardiovascular diseases, including AF, which is one of the most common cardiac arrhythmias globally. AF is strongly associated with an increased risk of stroke, heart failure (HF), and cardiovascular mortality. Although intensive blood pressure lowering has been shown to reduce adverse cardiovascular events, its effect on the risk of AF remains debated. Some studies suggest a beneficial effect, whereas others are inconclusive. Therefore, a comprehensive review and meta-analysis are needed to clarify these effects. Objective: This study aims to evaluate the impact of intensive blood pressure lowering on the incidence of atrial fibrillation (AF) in hypertensive patients. Methods: We performed a systematic review and meta-analysis by searching PubMed, EMBASE, Scopus, Web of Science, and the Cochrane Library up to September 2, 2024, for randomized controlled trials comparing intensive blood pressure lowering with standard treatment in hypertensive patients. Studies were included if participants were 40 year or older with systolic blood pressure between 130 and 180 mm Hg (1 mm Hg≈0.133 kPa). Data extraction was conducted by 2 independent researchers, and statistical analysis was performed using Review Manager (RevMan) 5.4. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated. A random-effects model was applied if heterogeneity was detected (I
> 50%). Results: A total of 6 randomized controlled trials involving 34,824 participants were included in the analysis. Intensive blood pressure lowering significantly reduced the risk of new-onset AF compared with standard treatment (RR = 0.76, 95% CI = 0.62-0.93, p < 0.01, I
= 0%). Reductions were also observed in stroke (RR = 0.71, 95% CI = 0.58-0.87, p < 0.005, I
= 7%), HF (RR = 0.67, 95% CI = 0.45-0.99, p = 0.05, I
= 53%), and nonfatal coronary events (RR = 0.80, 95% CI = 0.70-0.92, p < 0.005, I
= 39%). However, intensive blood pressure lowering had no significant effect on cardiovascular mortality or all-cause mortality compared with standard treatment. Discussion: Intensive blood pressure lowering significantly reduces the risk of AF and other cardiovascular events, such as stroke, HF, and nonfatal coronary events, particularly among high-risk hypertensive patients. These findings support the potential benefits of intensive blood pressure management in reducing AF incidence and improving overall cardiovascular outcomes, but the evidence is limited.
